BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
BioAge Labs, Inc.NASDAQ: BIOA
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 124.4% from a year ago
Short-term investments stood at $141.42M at the end of Q1 FY2026, up 124.4% from a year earlier and up 53.4% from the prior quarter.
Context
- Short-term investments amounted to 35.6% of total assets at the end of Q1 FY2026, up 17.2 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +124.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 92.21M USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.21M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +124.4% is the 2nd highest of 7, against a peer median of -71.1%.
- Short-term investments amounts to 35.6% of total assets for BIOA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $236.58M USD | -0.4% | -24.2% | 59.7% | |
| Mar 2026 | $176.69M USD | -42.3% | — | 66.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $141.42M USD | +124.4% | — | 35.6% |
| Mar 2026 | CA$52.35M CAD | +9403.7% | — | 8.7% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | +26.6% | 0.0% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | -100.0% | -63.7% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -71.1% | -24.2% | 0.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.